United States Patent 6,696,493 (L-Carnitine in Chronic Uremic Dialysis): Scope, Claim-by-Claim Boundaries, and US Patent Landscape

United States Patent 6,696,493 has claim scope centered on a specific dialysis-timed L-carnitine administration strategy for chronic uremic patients on periodic dialysis. The independent claim is anchored to (i) route and timing “at the conclusion of the dialysis into a venous return line,” (ii) dose range “10 to 20 mg/kg” (as L-carnitine or a pharmaceutically acceptable salt), (iii) a targeted pharmacodynamic outcome “restore… to a pre-dialytic level of at least 40 μM,” and (iv) a subsequent maintenance step that reduces dosing “sufficient to maintain” at the pre-dialytic level.

On the method side, the patent’s enforceable perimeter is likely narrower than generic “use of carnitine in dialysis” patents because it ties efficacy to a defined plasma concentration threshold and to a dialysis-session end-point administration mechanism. On the marketing side, it maps cleanly onto product-label “use” language for L-carnitine or acetyl-L-carnitine in dialysis settings only if label or clinical protocol aligns with the claimed timing, dose, and level targets.

What is the scope of US Patent 6,696,493 for preventing or treating carnitine deficiency in chronic uremic patients on dialysis?

Direct scope answer: The patent claims methods of preventing or treating carnitine deficiency in chronic uremic patients undergoing periodic dialysis by administering L-carnitine (or salts) directly into the venous return line at the end of a dialysis session, using 10–20 mg/kg to reach pre-dialytic plasma carnitine ≥40 μM (or higher dependent on dependent claims), followed by a reduced maintenance dosing strategy that maintains that pre-dialytic level.

Key claim elements that define infringement risk

The independent claim (Claim 1) is structured into four technological/clinical pillars:

Patient population
- “chronic uremic patients undergoing periodic dialysis”
Administration timing and route
- “at the conclusion of the dialysis into a venous return line after a dialysis session”
Dose regimen for repletion
- “from about 10 to about 20 mg/kg body weight of carnitine, calculated as L-carnitine, or… pharmaceutically acceptable salt”
Outcome-based target and maintenance
- “restore a level… to a pre-dialytic level of at least 40 μM”
- “thereafter reducing the amount… to a level sufficient to maintain carnitine levels to the pre-dialytic level”

Practical boundary: A protocol that differs on any of these pillars can materially move claim coverage. In particular:

If dosing occurs mid-dialysis or at non-venous-return-line routes, you move away from the literal language.
If the total dose is outside 10–20 mg/kg, you also reduce literal match.
If the clinician targets a different threshold (for example pre-dialysis <40 μM), you move away from the outcome requirement.

What do the independent claims of US 6,696,493 require: dose, timing, route, and plasma concentration thresholds?

Claim 1 (independent): full element map

Claim 1 requires all of the following in combination:

chronic uremic patient on periodic dialysis
carnitine deficiency prevention or treatment
administration occurs at the conclusion of dialysis
administration is into the venous return line after a dialysis session
initial dosing: 10–20 mg/kg L-carnitine (or salt)
pharmacodynamic requirement: restore to pre-dialytic plasma carnitine ≥40 μM
maintenance: reduce dosing after repletion to maintain the pre-dialytic level

Functional/measurement anchor: “pre-dialytic level” is a measurement timing concept. That is typically interpreted as a blood carnitine concentration measured before the next dialysis session, not during the session.

How “restore” may be construed

“Restore… to a pre-dialytic level” implies:

an initial state below the targeted level, then
a repletion period that achieves the pre-dialytic threshold.

This matters for prior-therapy arguments in litigation, since some protocols may already keep carnitine above threshold at baseline.

What additional limitations do the dependent claims add (twice weekly schedule, 3–4 weeks, 50 μM threshold, 5 mg/kg maintenance)?

Claim 2: twice-weekly schedule and time sequencing

Claim 2 adds a specific repeated administration pattern:

“on a weekly basis repeated twice a week every 44 hours, then after 68 hours.”

That pattern reads as a dosing cadence across dialysis intervals, not a generic “weekly” schedule.

Scope impact: Even if a party meets Claim 1 dose and thresholds, Claim 2 narrows to a timing cadence. For infringement on Claim 2, you would need matching session-to-session timing logic.

Claim 3: treatment duration

“continued for 3–4 weeks.”

Scope impact: Claim 3 narrows duration. A clinician using the same dose/timing but for a shorter course may avoid Claim 3.

Claim 4: higher target threshold

“pre-dialytic level… at least 50 μM.”

Scope impact: This is an efficacy threshold dependent on measurement. A regimen that stabilizes at 45–49 μM may satisfy Claim 1 but not Claim 4.

Claim 5: maintenance dosage amount

“maintenance dosage of about 5 mg/kg of carnitine… administered.”

Scope impact: Claim 5 narrows the maintenance dosing magnitude. The phrase “about” creates tolerance, but it still defines a numeric target that can be tested against actual clinical protocol.

Claim 6: patient selection based on initial pre-dialysis level

Claim 6 provides an additional trigger:

administering is “prompted by the patient demonstrating an initial pre-dialysis plasma carnitine level equal or lower than 50 μM.”

Scope impact: This ties treatment initiation to a baseline lab criterion. A regimen for patients above 50 μM at baseline does not fit this dependent claim.

Claim 7: tighter baseline trigger

initial pre-dialysis concentration “equal or lower than 40 μM.”

Scope impact: This further narrows the treatment initiation group.

How does Claim 6 differ from Claim 1: baseline trigger versus target outcome?

Claim 1 requires the end result (restore to pre-dialytic ≥40 μM) and a maintenance plan. Claim 6 adds that dosing is triggered by an initial condition (baseline pre-dialysis ≤50 μM). Claim 7 tightens the baseline trigger to ≤40 μM.

Scope consequence: A protocol might meet Claim 1’s outcome (restore to ≥40 μM) even if the starting point is above 50 μM. Claim 6/7 narrow the prescription population by baseline laboratory criteria.

What carnitine forms are covered: L-carnitine and salts only, or broader carnitine analogs?

Across Claims 1 and 6 the active is:

“carnitine, calculated as L-carnitine,” or
“pharmaceutically acceptable salt thereof.”

Coverage implication: The claim language is specific to L-carnitine (and salts). If a competitor uses a different carnitine-related entity (for example acetyl-L-carnitine where not “calculated as L-carnitine”), that may not satisfy the “calculated as L-carnitine” limitation.

Enforcement implication: If the product is acetyl-L-carnitine, the legal relevance hinges on whether it is treated as “carnitine, calculated as L-carnitine” under claim interpretation. The literal claim text is strongest for L-carnitine itself.

What patented subject matter does US 6,696,493 cover versus general “carnitine supplementation in dialysis” patents?

General supplementation patents often claim:

giving carnitine to dialysis patients to treat deficiency or symptoms, without:
- venous return-line end-of-session administration,
- tight dose ranges,
- concentration thresholds measured pre-dialysis,
- specific maintenance reductions to a defined pre-dialytic level.

US 6,696,493 is method-of-treatment with operational constraints. Its claim drafting is designed to convert a clinical concept into a reproducible dosing program.

How many US patents likely sit in the same claim space (dialysis carnitine dosing with plasma thresholds), and what claim types typically overlap?

Without the full US citation graph and Orange Book/FTO listings, the only reliable statement from your claim set is what type of patents this belongs to:

Method-of-use patents
- dialysis carnitine dosing protocols
- plasma concentration targets and measurement timing
Dosing regimen dependent patents
- specific mg/kg loading doses and maintenance doses
- specific dialysis-session schedules (e.g., 44-hour/68-hour intervals)
Selection/stratification dependent patents
- initiating based on baseline plasma carnitine thresholds (≤50 μM or ≤40 μM)
Administration route patents
- dosing into venous return line at end of session (a device-adjacent clinical workflow limitation)

The risk for generic entry under these patents typically arises if a generic label or off-label practice is alleged to follow the same protocol. For method patents, enforcement can target prescribers and dispenser systems depending on jurisdictional posture.

What is the likely patent expiration timing and exclusivity exposure for US 6,696,493?

This requires the patent’s filing/priority and maintenance status to calculate the exact expiration. Your prompt does not include those bibliographic fields, and the answer cannot be completed accurately from the claim text alone.

What generic entry risks exist for L-carnitine regimens matching the claimed dialysis timing and plasma targets?

High-risk scenario (literal alignment):

A clinician administers L-carnitine into the venous return line at dialysis conclusion,
uses 10–20 mg/kg loading,
adjusts maintenance to keep pre-dialytic plasma carnitine ≥40 μM,
uses a schedule consistent with dependent claim cadence (if asserted),
and the patient’s baseline and measured levels match the dependent claim triggers if those are at issue.

Lower-risk scenario (protocol deviation):

Route differs (not venous return line).
Timing differs (not at dialysis conclusion).
Dose range deviates from 10–20 mg/kg loading.
The pre-dialytic target is not reached or is measured differently.
Maintenance dose does not approximate 5 mg/kg (for Claim 5).
Baseline trigger criteria are not met (for Claim 6/7).

What formulations or manufacturing methods are implicated by US 6,696,493?

This patent is directed to a method of preventing or treating carnitine deficiency via administration timing and dosing strategy. It does not, from the claim text provided, claim:

a specific formulation composition (e.g., excipient system),
a manufacturing process,
a device claim (dialysis circuit configuration) in claim language.

That said, the “venous return line” limitation creates a functional dependence on dialysis circuit handling. Still, the active is L-carnitine (or salt), so formulation scope is not the primary battleground suggested by the provided claims.

What patent litigation and challenges are likely relevant to this patent class?

This cannot be tied to US 6,696,493 specifically without litigation docket or assignment records. The claim class (method-of-treatment) commonly leads to disputes over:

whether a given clinical protocol follows the exact dosing/timing/route constraints, and
whether plasma concentration measurements match the thresholds “pre-dialytic level” requirements,
whether the accused practice infringes a dependent claim’s additional scheduling/dosing/duration thresholds.

What commercial implications follow for dialysis carnitine products and reimbursement decisions?

This patent’s enforceable commercial impact depends on:

whether a product’s label or clinical pathways reflect the claimed regimen,
whether providers treat carnitine levels to pre-dialysis targets as a standard practice consistent with the claims.

If reimbursement protocols drive the same titration and dosing schedule, the patent can be leveraged in licensing or settlement contexts. If practice is more heterogeneous, enforceability shifts to case-by-case evidence of actual administration and lab targets.

How does US 6,696,493 compare with adjacent regimen claims: threshold 40 μM vs 50 μM, and maintenance dose levels?

Comparison matrix using your claim set

Claim	Added narrowing variable	Parameter	Literal threshold/value
1	Baseline restoration and maintenance (core)	pre-dialytic target	≥ 40 μM
4 (dep.)	Stronger efficacy	pre-dialytic target	≥ 50 μM
5 (dep.)	Maintenance magnitude	maintenance dose	~ 5 mg/kg
6 (dep.)	Treatment initiation population	baseline pre-dialysis	≤ 50 μM
7 (dep.)	Stronger selection criterion	baseline pre-dialysis	≤ 40 μM
2 (dep.)	Scheduling cadence	session-to-session timing	every 44 hours, then after 68 hours
3 (dep.)	Duration	treatment length	3–4 weeks

Portfolio insight: If an accused regimen meets Claim 1’s minimum target (≥40 μM) but not Claim 4 (≥50 μM) or not Claim 5 (~5 mg/kg maintenance), a party can still face exposure under Claim 1, but not under narrower dependent claims.

Key Takeaways

US 6,696,493 claims a specific dialysis-end administration method for L-carnitine to treat or prevent carnitine deficiency in chronic uremic patients.
The independent claim is anchored by four combined constraints: venous return line at dialysis conclusion, 10–20 mg/kg loading, pre-dialytic plasma carnitine restoration to ≥40 μM, and reduced maintenance dosing to maintain that pre-dialytic level.
Dependent claims tighten scope via specific dosing cadence, 3–4 week duration, higher pre-dialytic targets (≥50 μM), maintenance dose (~5 mg/kg), and baseline selection triggers (≤50 μM or ≤40 μM).
The enforceable perimeter is likely narrower than broad “carnitine supplementation in dialysis” IP because it requires both protocol mechanics (timing/route) and measurable concentration thresholds tied to pre-dialysis lab timing.

FAQs

1) What does “pre-dialytic level” mean in US 6,696,493?
It refers to the plasma carnitine concentration measured before a dialysis session, which the claims use as the decision threshold (≥40 μM in Claim 1).

2) Can a regimen that targets intradialytic carnitine levels infringe US 6,696,493?
Infringement is strongest when the protocol restores and maintains the claimed pre-dialytic plasma levels.

3) Does US 6,696,493 cover acetyl-L-carnitine?
The claims explicitly recite “L-carnitine, calculated as L-carnitine,” and pharmaceutically acceptable salts, so coverage depends on whether the asserted compound falls within that definition.

4) Are the dependent claim schedules required if only Claim 1 is asserted?
No. Dependent claims add additional limitations (44-hour/68-hour cadence, 3–4 week duration). Claim 1 is evaluated on its own elements.

5) What is the main litigation proof for method claims like US 6,696,493?
Evidence that the accused protocol followed the claimed dosing route and timing (venous return line at dialysis conclusion), the mg/kg dosing range, and produced the claimed pre-dialytic plasma carnitine targets measured at the appropriate time.

References

United States Patent 6,696,493 (provided claim text).

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	3050201	⤷ Start Trial
Canada	2381187	⤷ Start Trial
European Patent Office	1257266	⤷ Start Trial
World Intellectual Property Organization (WIPO)	0152836	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 6,696,493

Summary for Patent: 6,696,493